Investors & Media

Corporate Profile

With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to orphan pulmonary and fibrosis indications. Aileron intends to advance Lung’s pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • February 15, 2024
    Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
  • February 1, 2024
    Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
  • October 31, 2023
    Aileron Therapeutics Announces Acquisition of Lung Therapeutics


  • February 15, 2024 at 4:30 PM EST

    KOL Event: Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis

    Read More
  • October 31, 2023 at 1:30 PM EDT

    Aileron Therapeutics' Acquisition of Lung Therapeutics Conference Call

    Read More